Nerve Growth Factor (NGF) potently prevents the death and augments the functional state of cholinergic neurons of the basal forebrain, a cell population that undergoes extensive degeneration in Alzheimer disease (AD). A recent Phase I clinical trial of ex vivo NGF gene delivery (via constitutively NGF secreting fibroblasts inserted into human basal forebrain) in early AD patients reported: 1) robust ?trophic? (growth) responses of human cholinergic neurons to NGF in the AD brain, 2) intriguing possible effects on cognition sustained over at least a 22 month period, and 3) a significant increase in cortical glucose uptake on PET scan in treated subjects. A second phase I trial of in vivo NGF gene delivery has recently been conducted in 6 patients, utilizing Adeno-Associated Virus (AAV) vectors that exhibit superior properties of long-term gene expression in the brain compared to the vector used in the ex vivo NGF trial;this trial has confirmed the safety of in vivo AAV-NGF gene delivery in AD, with post-treatment follow-up ranging from six to 18 months in six subjects. We now propose a Phase II randomized clinical trial of AAV-NGF Gene Delivery in AD to test the hypothesis that NGF gene delivery, by preventing cell loss and augmenting neuronal function, will modify AD clinical progression. Given the novel nature of this technology and its requirement for stereotaxic delivery into patients, this trial will focus on objectives related to ?scaling up? for larger efficacy trials, including: 1) expanding the technology's implementation to several new clinical sites, 2) assessing potential effect size, and 3) evaluating positron emission tomography (PET) as a potential marker of neurotrophic activity and correlate of efficacy. The proposed trial is a 24-month, prospective, randomized, double-blind, sham- controlled, multi-center Phase II clinical trial of AAV-NGF In Vivo Gene Therapy for AD. Fifty patients with mild to moderate AD will be randomly assigned to receive 2 intracerebral injections of AAV-NGF into each NBM of each hemisphere, or a sham- surgery control procedure (bilateral scalp incision and partial burr holes). Outcome measures include cognitive, clinical and safety assessments, as well as PET scanning measures. If the primary analysis is favorable, subjects assigned to the sham surgery arm will be offered active AAV-NGF treatment. Project Narrative This project is a randomized controlled clinical trial to determine the efficacy and safety of NGF gene delivery for the treatment of Alzheimer's disease. Alzheimer's disease is among the most important health problems worldwide, with steadily rising prevalence as populations age. Effective disease-modifying treatment is sorely needed.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAG1-ZIJ-7 (O7))
Program Officer
Ryan, Laurie M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Diego
Schools of Medicine
La Jolla
United States
Zip Code
Chen, Yun-Fei; Ni, Xiao; Fleisher, Adam S et al. (2018) A simulation study comparing slope model with mixed-model repeated measure to assess cognitive data in clinical trials of Alzheimer's disease. Alzheimers Dement (N Y) 4:46-53
Insel, Philip S; Mattsson, Niklas; Mackin, R Scott et al. (2016) Accelerating rates of cognitive decline and imaging markers associated with ?-amyloid pathology. Neurology 86:1887-96
Risacher, Shannon L; McDonald, Brenna C; Tallman, Eileen F et al. (2016) Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. JAMA Neurol 73:721-32
Insel, Philip S; Donohue, Michael C; Mackin, R Scott et al. (2016) Cognitive and functional changes associated with A? pathology and the progression to mild cognitive impairment. Neurobiol Aging 48:172-181
Reiman, Eric M; Langbaum, Jessica B; Tariot, Pierre N et al. (2016) CAP--advancing the evaluation of preclinical Alzheimer disease treatments. Nat Rev Neurol 12:56-61
Insel, Philip S; Mattsson, Niklas; Donohue, Michael C et al. (2015) The transitional association between ?-amyloid pathology and regional brain atrophy. Alzheimers Dement 11:1171-9
Henley, David B; Dowsett, Sherie A; Chen, Yun-Fei et al. (2015) Alzheimer's disease progression by geographical region in a clinical trial setting. Alzheimers Res Ther 7:43
Hampel, Harald; Schneider, Lon S; Giacobini, Ezio et al. (2015) Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. Expert Rev Neurother 15:83-105
Grill, Joshua D; Raman, Rema; Ernstrom, Karin et al. (2015) Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials. Alzheimers Res Ther 7:39
Hampel, Harald; Lista, Simone; Teipel, Stefan J et al. (2014) Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. Biochem Pharmacol 88:426-49

Showing the most recent 10 out of 21 publications